冠状病毒相关靶点的PET成像研究进展  

PET Imaging Study of Coronavirus-related Targets

作　　者：丁缙 李大鹏 张倩 孟祥溪 刘特立 杨志[1] 朱华[1] DING Jin;LI Dapeng;ZHANG Qian;MENG Xiangxi;LIU Teli;YANG Zhi;ZHU Hua(Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education),Key Laboratory for Research and Evaluation of Radiopharmaceuticals(National Medical Products Administration),Department of Nuclear Medicine,Peking University Cancer Hospital&Beijing Institute of Cancer Prevention and Treatment,Beijing 100142,China)

机构地区：[1]北京大学肿瘤医院暨北京市肿瘤防治研究所核医学科、国家药监局放射性药物研究与评价重点实验室、恶性肿瘤发病机制及转化研究教育部重点实验室,北京100142

出　　处：《药学进展》2023年第6期464-470,共7页Progress in Pharmaceutical Sciences

基　　金：北京市百千万人才工程培养经费资助A类项目(No.2019A38)。

摘　　要：分子影像技术作为新兴发展的非侵入性、活体、动态的临床诊断技术,是现代医疗中达到可视化和诊疗一体化的关键技术。其中正电子发射计算机断层扫描(PET)以其超高的灵敏度和在核医学应用中的准确性,经过数十年的发展已成为当代临床应用的前沿与核心的分子显像技术,其在临床诊疗中的指导作用和重要应用为新型冠状病毒的抑制剂和靶向探针的研发提供了实践基础。综述新型冠状病毒潜在的受体如人血管紧张素转换酶等蛋白靶点、核苷类受体和抑制剂进行的系列分子影像的生物和临床研究进展,以期为新型冠状病毒诊疗一体化药物的研发提供参考。Molecular imaging technology,as a newly developed non-invasive,in vivo and dynamic clinical diagnosis technology,is the key technology to achieve visualization and integration of diagnosis and treatment in modern medical practice.Among them,positron emission computed tomography(PET),with its ultra-high sensitivity and accuracy in nuclear medicine application,has become the forefront and core molecular imaging technology in current clinical application after decades of development.Its guiding role and important application in clinical diagnosis and treatment provide a practical basis for the research and development of inhibitors and targeting probes of novel coronavirus.The biological and clinical research progress of series of molecular imaging of potential receptors of novel coronavirus,such as human angiotensin converting enzyme and other protein targets,nucleoside receptors and inhibitors,was reviewed,in order to provide reference for the research and development of integrated drugs for the diagnosis and treatment of novel coronavirus.

关 键 词：严重急性呼吸道综合征冠状病毒2 人血管紧张素转换酶2 表皮生长因子受体 整合素β6 血管内皮生长因子A 

分 类 号：R816.4[医药卫生—放射医学]